http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
Landmark TAILORx Results Aid in Assessing the Effect of Chemotherapy in Women with Early-stage Breast Cancer and Oncotype DX Breast Recurrence Score® Results of 11 to 25
-
Genomic Health Announces 2017 Fourth Quarter and Year-end Financial Results, Provides 2018 Financial Outlook
-
Biocartis Group NV: BIOCARTIS ANNOUNCES 2017 RESULTS AND 2018 OUTLOOK
-
Biocartis Group NV: BIOCARTIS ANNOUNCES 2017 RESULTS AND 2018 OUTLOOK
-
Genomic Health Expands Offering to Prostate Cancer Patients with Launch of Oncotype DX® AR-V7 Nucleus Detect™ Test to Predict Treatment Response in Metastatic Disease
-
Genomic Health to Announce Fourth Quarter and Year-End 2017 Financial Results and Host Conference Call on Thursday, March 8, 2018
-
Oncotype DX® Genomic Prostate Score™ Test Increases Use of Active Surveillance by 30 Percent in Low-risk Patients, Resulting in Greater Adherence to Guideline-based Care
-
Genomic Health to Present at the 36th Annual J.P. Morgan Healthcare Conference
-
Genomic Health Presents New Data Demonstrating Value of Oncotype DX® to Optimize Breast Cancer Outcomes and Reduce Treatment Burden throughout Disease Continuum
-
Genomic Health (GHDX) Reports Research Collaboration with Janssen Pharmaceuticals (JNJ) to Evaluate the Oncotype DX
-
Genomic Health Announces Research Collaboration with Janssen Pharmaceuticals to Evaluate the Oncotype DX® Genomic Prostate Score™ Test for Potential Drug Development
-
Genomic Health Announces Presentation of 10 Oncotype DX® Studies at the 2017 San Antonio Breast Cancer Symposium Demonstrating Test's Unique Value in Predicting Neoadjuvant Treatment Benefit and Guid
-
Genomic Health and Cleveland Diagnostics Announce Strategic Collaboration to Develop and Commercialize New Prostate Cancer Tests
-
Genomic Health to Present at the 29th Annual Piper Jaffray Healthcare Conference
-
Biocartis Group NV: BIOCARTIS Q3 2017 BUSINESS UPDATE
-
Genomic Health Announces Third Quarter 2017 Financial Results and Reports Recent Business Progress
-
Genomic Health to Announce Third Quarter 2017 Financial Results and Host Conference Call on Wednesday, November 8, 2017
-
Genomic Health (GHDX) & Biocartis Reports Agreement to Develop an Idylla IVD Oncotype DX Breast Cancer Test to Broaden Global Patient Access
-
Biocartis Group NV: Genomic Health and Biocartis Announce Agreement to Develop an Idylla(TM) IVD Oncotype DX® Breast Cancer Test to Broaden Global Patient Access
-
Genomic Health and Biocartis Announce Agreement to Develop an Idylla™ IVD Oncotype DX® Breast Cancer Test to Broaden Global Patient Access
-
Genomic Health (GHDX) Presents Data Showing Importance of Oncotype DX Breast Recurrence Score Test in Predicting Outcomes Across Patient Populations at ESMO
-
Genomic Health Presents Data Demonstrating Importance of Oncotype DX Breast Recurrence Score® Test in Predicting Outcomes Across Patient Populations at ESMO 2017
-
Genomic Health Continues to Pioneer Genomic-based Cancer Diagnostics with Multiple Presentations at ESMO 2017 Congress
-
Genomic Health to Present at the 2017 Wells Fargo Healthcare Conference
-
Genomic Health (GHDX) Says Medicare Establishes Final Local Coverage Determination (LCD) for Use of Oncotype DX GPS Test
-
Medicare Establishes Final Local Coverage Determination (LCD) for Use of the Oncotype DX® Genomic Prostate Score™ Test in Patients with Favorable Intermediate-risk Prostate Cancer Effective October
-
Genomic Health Announces Second Quarter 2017 Financial Results and Reports Recent Business Progress
-
Genomic Health to Announce Second Quarter 2017 Financial Results and Host Conference Call on Tuesday, August 1, 2017
-
Updated St. Gallen International Breast Cancer Guidelines Reinforce Important Role of Genomic Testing in Treatment of Early Breast Cancer
-
Genomic Health Presents Data Further Demonstrating Ability of Oncotype DX® Tests to Optimize Outcomes in Patients Across Cancer Types
-
Genomic Health Announces Presentation of Eight Oncotype DX® Studies at the 2017 American Society of Clinical Oncology Annual Meeting Reinforcing Unique Impact Across Cancer Types
-
Genomic Health to Present at Jefferies 2017 Healthcare Conference
-
Genomic Health (GHDX) Prospective Oncotype DX Genomic Prostate Score Test Data Presented at American Urological Association (AUA) 2017 Annual Meeting
-
Prospective Oncotype DX® Genomic Prostate Score™ Test Data Presented at AUA and Published in Urology Establish Test's Ability to Increase Use and Persistence on Active Surveillance in Prostate Canc
-
Oncotype DX® Genomic Prostate Score™ (GPS) Test Predicts 10-year Risk of Prostate Cancer-specific Death and Metastases in Patients with Early-stage Disease
-
Genomic Health to Present at Bank of America Merrill Lynch 2017 Health Care Conference
-
Genomic Health Announces First Quarter 2017 Financial Results and Reports Recent Business Progress
-
Genomic Health (GHDX) Announces Favorable Draft LCD on Medicare Coverage for Use of Oncotype DX GPS in Patients with Favorable Intermediate-risk Prostate Cancer
-
Genomic Health Announces Favorable Draft Local Coverage Determination (LCD) on Medicare Coverage for Use of Oncotype DX® Genomic Prostate Score™ in Patients with Favorable Intermediate-risk Prostat
-
Genomic Health Announces Upcoming Presentation of Four Oncotype DX® Studies Including New Validation on Its Ability to Predict Prostate Cancer-specific Death and Metastases
-
Genomic Health to Announce First Quarter 2017 Financial Results and Host Conference Call on Tuesday, May 9, 2017
-
Genomic Health (GHDX) Says Oncotype DX Predicts 10-year Risk of Developing Metastatic Prostate Cancer in Low- and Intermediate-risk Patients
-
Oncotype DX® Predicts 10-year Risk of Developing Metastatic Prostate Cancer in Low- and Intermediate-risk Patients
-
Genomic Health (GHDX) Reports Publishing of Outcomes Results from SEER Registry
-
Published Outcomes Results from SEER Registries Indicates That Many Node-positive Breast Cancer Patients Can Avoid Chemotherapy Based on Oncotype DX® Results
-
Multiple Presentations at 15th St. Gallen International Breast Cancer Conference Demonstrate Significant Impact of Oncotype DX Breast Recurrence Score® in Reducing Burden and Cost of Chemotherapy
-
Genomic Health to Present at the Cowen and Company 37th Annual Health Care Conference
-
Four New Studies of Oncotype DX® Genomic Prostate Score™ (GPS) Reconfirm Value of Test in Guiding Early-stage Prostate Cancer Risk Assessment and Treatment Selection
-
Genomic Health Announces 2016 Fourth Quarter and Year-End Financial Results, Provides 2017 Financial Outlook
-
Genomic Health to Announce Fourth Quarter and Year-End 2016 Financial Results and Host Conference Call on Tuesday, February 14, 2017

